Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma

被引:1
|
作者
Caro, Jessica [1 ]
Cairns, David [2 ]
Menzies, Tom [2 ]
Boyle, Eileen [1 ]
Pawlyn, Charlotte [3 ]
Cook, Gordon [2 ]
Kaiser, Martin [3 ]
Walker, Brian A. [4 ]
Owen, Roger [5 ]
Jackson, Graham H. [6 ]
Morgan, Gareth J. [1 ]
Heaney, Jennifer [7 ]
Drayson, Mark [7 ]
Davies, Faith E. [1 ]
机构
[1] NYU Langone Hlth, Perlmutter Canc Ctr, 168 E 34th St, New York, NY 10016 USA
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, W Yorkshire, England
[3] Inst Canc Res, London, England
[4] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[5] St James Univ Hosp, Leeds, W Yorkshire, England
[6] Newcastle Univ, Dept Hematol, Newcastle Upon Tyne, Tyne & Wear, England
[7] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷 / 04期
关键词
Immunosuppression; myeloma; infection; plasma cell disorder; monoclonal protein; RISK; THALIDOMIDE; THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE;
D O I
10.1016/j.clml.2021.10.008
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunoparesis is associated with poor survival in myeloma (MM). We demonstrate that the etiologic cytogenetic abnormality influences the degree and clinical impact of immunoparesis in newly diagnosed patients in a large clinical trial. As the depth of IgM immunoparesis impacts survival for hyperdiploid patients, this may be used to further risk-stratify this cytogenetic subgroup of patients for future clinical decisions. Introduction/Background: Immunoparesis, or low polyclonal immunoglobulin levels, is commonly seen in multiple myeloma (MM), and is associated with poor clinical outcomes. MM can be divided into subgroups with distinct biology and outcomes based on etiologic cytogenetic abnormalities. These include hyperdiploidy and translocations of t(11;14), t(4;14), t(14;16), and t(14;20), with the latter 3 associated with high-risk disease. We hypothesized that the different etiologic cytogenetic abnormalities drive bone marrow microenvironmental changes, resulting in different degrees of immunoparesis, and subgroup-dependent effects on clinical outcomes. Materials and Methods: We performed a retrospective review of 985 newly diagnosed patients enrolled in the Myeloma IX and XI trials. Immunoglobulin levels, survival outcomes, and infection rates were evaluated for each cytogenetic subgroup. Results: A significant proportion of patients with high-risk t(4;14), t(14;16), or t(14;20) had suppressed polyclonal immunoglobulins compared to standard-risk patients with hyperdiploidy or t(11;14). The clinical impact of immunoparesis depended on the cytogenetic subgroup, with the degree of IgM suppression effecting progression-free and overall survival only in the hyperdiploid subgroup. There was no significant difference in infection rates amongst the etiologic subgroups. Conclusion: These findings demonstrate that the etiologic cytogenetic subgroup influences the degree and clinical impact of immunoparesis. This suggests that the underlying cytogenetic abnormality affects remodeling of the bone marrow plasma cell niche, resulting in suppressed normal plasma cell function, and low immunoglobulin levels.
引用
收藏
页码:E279 / E284
页数:6
相关论文
共 50 条
  • [1] Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma
    Caro, Jessica
    Cairns, David
    Menzies, Tom
    Pawlyn, Charlotte
    Boyle, Eileen M.
    Morgan, Gareth
    Cook, Gordon
    Kaiser, Martin F.
    Owen, Roger G.
    Gregory, Walter M.
    Jackson, Graham H.
    Walker, Brian
    Heaney, Jennifer Lj
    Drayson, Mark T.
    Davies, Faith E.
    BLOOD, 2020, 136
  • [2] THE FREQUENCY OF CYTOGENETIC ABNORMALITIES AND THEIR IMPACT ON OVERALL SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA.
    Garifullin, A.
    Voloshin, S.
    Martynkevich, I.
    Bessmeltsev, S.
    Martynenko, L.
    Kleina, E.
    Salogub, G.
    Karyagina, E.
    Schmidt, A.
    Kuvshinov, A.
    Abdulkadyrov, K.
    HAEMATOLOGICA, 2015, 100 : 733 - 733
  • [3] The Impact Of Immunoparesis On Outcomes Of Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review
    Siwakoti, Ashmita
    Khadka, Sukhdev
    Grimshaw, Alyssa
    Giri, Smith
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB78 - AB78
  • [4] Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma
    Smallbone, Portia
    Clugston, Stephanie
    De Kraa, Rebecca
    Purtill, Duncan
    Wright, Matthew
    Leahy, Michael F.
    Sidiqi, M. Hasib
    BLOOD, 2020, 136
  • [5] Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
    Sorrig, Rasmus
    Klausen, Tobias W.
    Salomo, Morten
    Vangsted, Annette J.
    Frolund, Ulf Christian
    Andersen, Kristian T.
    Klostergaard, Anja
    Helleberg, Carsten
    Pedersen, Robert S.
    Pedersen, Per T.
    Helm-Petersen, Sissel
    Teodorescu, Elena Manuela
    Preiss, Birgitte
    Abildgaard, Niels
    Gimsing, Peter
    PLOS ONE, 2017, 12 (12):
  • [6] Immunoparesis in Newly Diagnosed Multiple Myeloma and Its Impact on Clinical Outcome: A Real-World Experience
    Mahapatra, Manoranjan
    Verghese, Renjith Mathew
    Dhawan, Rishi
    Das, Jasmita
    Aggarwal, Mukul
    Kumar, Pradeep
    Kumar, Ganesh
    Seth, Tulika
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S579 - S579
  • [7] PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Binder, M.
    Rajkumar, S. V.
    Ketterling, R. P.
    Dispenzieri, A.
    Lacy, M. Q.
    Gertz, M. A.
    Buadi, F. K.
    Hayman, S. R.
    Hwa, Y. L.
    Zeldenrust, S. R.
    Lust, J. A.
    Russell, S. J.
    Leung, N.
    Kapoor, P.
    Go, R. S.
    Gonsalves, W. I.
    Kyle, R. A.
    Kumar, S. K.
    HAEMATOLOGICA, 2017, 102 : 107 - 107
  • [8] Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma
    Binder, Moritz
    Rajkumar, S. Vincent
    Ketterling, Rhett P.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Gertz, Morie A.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Hwa, Yi L.
    Zeldenrust, Steven R.
    Lust, John A.
    Russell, Stephen J.
    Leung, Nelson
    Kapoor, Prashant
    Go, Ronald S.
    Gonsalves, Wilson I.
    Kyle, Robert A.
    Kumar, Shaji
    BLOOD, 2016, 128 (22)
  • [9] Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study
    Wang, Yiting
    Wu, Yong
    Xu, Zhenshu
    Zhou, Huarong
    Chen, Yuanzhong
    Zhan, Rong
    HEMATOLOGY, 2020, 25 (01) : 176 - 180
  • [10] LECULAR CYTOGENETIC TECHNIQUES IN IDENTIFICATION OF GENETIC ABNORMALITIES AMONG NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
    Al-Maeen, Abdul Rahman
    Al-Majed, Mohammed
    Khojah, Osamah
    Al-Khayat, Adnan
    Al-Harbi, Ahmed
    Al-Balwi, Mohammed
    Al-Atawi, Nasser
    Al-Suhaibani, Ahmed
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 5 - 5